

### **Amendments to the Claims**

This listing of claims replaces all prior versions and listings of claims in the application:

#### **Listing of Claims:**

15. **(Canceled)**

16. **(Previously Presented)** A method for treating a mammal suffering from a localized bacterial infection, a bacterial-related disease, or both, comprising locally administering a therapeutically effective amount of a composition comprising at least one granulocyte-macrophage-colony stimulating factor (GM-CSF) polypeptide;

wherein the bacterial infection or bacterial-related disease is selected from periodontal disease or sinusitis.

17. **(Canceled)**

18. **(Previously Presented)** The method of claim 16, wherein the periodontal disease is gingivitis or periodontitis.

19-20. **(Canceled)**

21. **(Previously Presented)** The method of claim 16, wherein the composition is suitable for administration via injection through the mucosal lining of the gingival or by application in a periodontal pocket.

22. **(Previously Presented)** The method of claim 16, wherein said GM-CSF is present in the composition in a unit dosage amount of 5 µg to 800 µg.

23. **(Previously Presented)** The method of claim 22, wherein the unit dosage amount is 50  $\mu\text{g}$  to 100  $\mu\text{g}$ .

24. **(Previously Presented)** The method of claim 16, wherein the composition is administered at intervals ranging from once a day to once every third week.

25. **(Previously Presented)** The method of claim 16, wherein the composition is administered a total of 1 to 3 times for a period of one week.

26. **(Previously Presented)** The method of claim 16, wherein the composition comprises a therapeutically effective amount of at least one other active ingredient.

27-31. **(Canceled)**